Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Kadmon, a Sanofi Company
Kadmon, a Sanofi Company
Industry · 14 registered clinical trials.
Status
Trial
Phase
Started
Withdrawn
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Na
Chronic Graft Versus Host Disease
Phase 2
2025-06-16
Terminated
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR4
Solid Tumor
Phase 1
2023-03-06
Completed
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy
Immune System Disorder, Healthy Volunteers
Phase 1
2022-07-27
Completed
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Chronic Graft-versus-host-disease
Phase 2
2022-02-23
Terminated
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Phase 2
2021-03-03
Completed
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impai
Hepatic Impairment
Phase 1
2019-12-11
Terminated
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Phase 2
2019-06-26
Terminated
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Chronic Graft-versus-host-disease
Phase 2
2018-10-11
Completed
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
Autosomal Dominant Polycystic Kidney, ADPKD
Phase 2
2017-10-12
Completed
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host
Graft vs Host Disease
Phase 2
2016-09-15
Completed
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjec
Immune System Disorder (Healthy Volunteer)
Phase 1
2014-03-28
Completed
A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopaus
Immune System Disorder (Healthy Volunteer)
Phase 1
2013-11-21
Completed
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidn
Polycystic Kidney, Autosomal Dominant
Phase 1 / Phase 2
2012-10-11
Completed
A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
Immune System Disorder (Healthy Volunteer)
Phase 1
2009-09-21